Table 1. Summary of the clinical, laboratory, and pathology features of 7 patients (including the current case report) presenting with glomerulopathies associated with pulmonary alveolar proteinosis.
| Reference | Age/Sex | Type of acquired PAP | Relevant serological studies | Treatment of PAP | Serum creatinine (mg/dL) | Urinary protein finding | Kidney pathology finding | Specific treatment | Outcome |
|---|---|---|---|---|---|---|---|---|---|
| Ganguli et al. [27] (1972) | 21/M | Idiopathic | – | None | – | 2+ protein | Amyloidosis* | Prednisone | Death |
| Parto et al. [18] (1994) | 10/F | Secondary (lysinuric protein intolerance | – | None | – | 2.2 g/L | Diffuse Glomerulonephritis* | None | Death |
| 13/F | Secondary (lysinuric protein intolerance | – | None | 0.85 | – | Mesangial Glomerulonephritis* | None | Death | |
| 7/F | Secondary (lysinuric protein intolerance | – | None | 3.15 | – | Membranous nephropathy* | None | Death | |
| Witzke et al. [28] (2004) | 38/F | Secondary (immunodeficiency syndrome with absence of monocytes) | – | Whole-lung lavage | Normal | 4.2 g/day | Membranous nephropathy | Prednisone | Death |
| Yamada et al. [29] (2007) | 47/F | Secondary | Absence of anti-GM-CSF antibody; presence of anti-α enolase antibody | None | 0.56 | 3.2 g/day | Membranous nephropathy | None | Spontaneous remission of PAP and nephrotic syndrome |
| Sewaralthahab (present case) (2014) | 43/F | Idiopathic | Absence of anti-PLA2R antibody | Whole-lung lavage and sargramostim therapy with clinical remission | 0.74 | 3.1 g/g of creatinine | Membranous nephropathy | De-escalation of sargramostim therapy | Remission of nephrotic syndrome |
PAP = pulmonary alveolar proteinosis; M = male; F = female; GM-CSF = granulocyte-macrophage colony stimulating factor; Note: Conversion factor for units: SCr in mg/dL to mmol/L, 388.4. *by autopsy.